SISRAM MED (01696.HK) shares plunged 5.29% in the pre-market trading session on Thursday, following the release of the company's underwhelming interim results for the first half of 2025. The medical aesthetics technology company reported a significant decline in profitability, sparking concerns among investors.

According to the financial report released late Wednesday, SISRAM MED's revenue for the six months ended June 30, 2025, decreased by 1.9% year-over-year to $165 million. More alarmingly, the profit attributable to owners of the parent company plummeted by 41.3% to $6.426 million, compared to the same period last year. The company's basic earnings per share also fell to 1.37 US cents.

The disappointing results were primarily attributed to challenging market conditions in North America, including high interest rates and weak consumer sentiment. Additionally, the company faced headwinds from transportation restrictions in June due to regional tensions, which led to slight delays in revenue recognition. The gross profit margin also declined from 62.4% to 60.0%, mainly due to a strategic shift in product mix and higher material costs. Despite growth in international markets and a robust order backlog, these positive factors were not enough to offset the negative impact on the company's overall performance, leading to the sharp decline in stock price as investors reassessed their positions.